Verastem Inc (FRA:2VSA)
€ 3.7 -0.34 (-8.42%) Market Cap: 158.44 Mil Enterprise Value: 109.90 Mil PE Ratio: 0 PB Ratio: 13.49 GF Score: 32/100

Verastem, Inc. - Special Call Transcript

Jan 08, 2020 / 09:00PM GMT
Release Date Price: €19.64 (+42.06%)
Operator

Good afternoon, and welcome to the Verastem Oncology Conference Call. Please be advised that this call is being recorded at the company's request and will be available on the company's website for a period of 90 days from today.

At this time, I would like to introduce Mr. John Doyle, Vice President of Investor Relations and Finance at Verastem Oncology. Please go ahead.

John Doyle
Verastem, Inc. - VP of IR & Finance

Welcome, everyone, and thank you for joining us this afternoon for Verastem Oncology's Defactinib Update. Before we begin our formal comments, I'll remind you that we will be making forward-looking assertions during today's call that represent the company's intentions, expectations or beliefs concerning future events which constitute forward-looking statements for the purpose of the safe harbor provisions under the Private Securities Litigation Reform Act of '95. All forward-looking statements are subject to factors, risks and uncertainties such as those detailed in today's press release announcing this call and in our filings with the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot